Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

VCPro Database 2014 (17th Edition) Now Available! Newly released


Venture Capital Deals Spreadsheet Now Available Newly released


 

Invitae Completes $40 Million Series E Financing

-- Financing to accelerate ongoing development of company’s clinical genetic tests and expansion into global markets --

SAN FRANCISCO, December 10, 2013-- Invitae Corporation, a genetic diagnostics company, today announced the completion of a $40 million Series E financing. Invitae will use the financing to accelerate the ongoing development of the company’s clinical genetic tests for hereditary disorders, including oncology, cardiology, neurology and pediatric medicine. Invitae will also focus on expanding to international markets.

Investors participating in the Series E round include Genomic Health, Inc. (GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capital, Casdin Capital, among others.

“Invitae is making significant progress in expanding our genetic testing services and executing on our business plan. With the support of our new and existing investors, this financing will allow us to expand our offering of genetic tests and build on our commercial capabilities,” said Randy Scott, PhD, founder and chief executive officer of Invitae. “This financing will help us to accelerate our plans to reinvent genetic testing by making it more affordable and accessible than ever before, and, ultimately, it will help us achieve our goal of transforming multi-use genetic testing into routine medical practice.”

About Invitae Corporation

Specializing in genetic diagnostics for hereditary disorders, Invitae’s mission is to make multi-use genetic testing more accessible and affordable than ever before.

The company is pursuing a strategy over the next several years to aggregate all the world's medical genetic tests (>3,000 known Mendelian inherited conditions) into a single assay at a lower cost than most single gene tests today.

This capability is increasingly enabled by the rapid advancements in DNA sequencing technology. Invitae hopes to lead the way from an era of genetic scarcity to genetic abundance to significantly improve healthcare worldwide.

Invitae has raised $87 million from investors, including Thomas, McNerney & Partners, Genomic Health, Inc. (NASDAQ: GHDX), Genesys Capital, Casdin Capital, Redmile Group and Randy Scott.

For further information, please visit www.invitae.com.

Contact:
Invitae Corporation
Katherine Stueland, 206-226-0672
pr@invitae.com
or
BrewLife
Paul Laland, 415-946-1071
plaland@brewlife.com


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals New
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

Venture Capital StarterPak
VC Pitch
Private Placement Memorandum
Confidentiality Agreement Package
Series A Preferred Term Sheet
Bridge Financing Contract
Employment Agreements
Understanding Employee Stock Options

Business Plan Tools

Free Business Plan Template
Sample Business Plans
Business Plan Pro

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer